Cancer diagnostic specialist Exact Sciences (NASDAQ: EXAS) has lagged the market over the past three years. The pandemic and the economic troubles that followed disrupted the company's operations, and the healthcare leader remains unprofitable. However, one famous name on Wall Street continues to have faith in Exact Sciences.

That person is Cathie Wood, CEO of Ark Invest, an investment management firm that still owns Exact Sciences' shares. There are great reasons to follow Wood's lead; Exact Sciences could deliver excellent results over the long run. Let's find out why.

Continue reading

Source Fool.com